Search

Lebrikizumab

Lebrikizumab is a monoclonal antibody that binds to IL-13 with high affinity and slow off-rate. It binds to a different epitope compared tralokinumab. On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolesc...